Do you use gene expression profiling for premenopausal women with hormone receptor positive breast cancer with 1-3 positive lymph nodes?

I do use gene expression profiling in premenopausal women with 1-3 nodes positive.

Premenopausal women represented 33% of all women in MINDACT (NEJM, 2016) (about 2100, a substantial number) and more than half of these premenopausal women had low genomic risk (and therefore a median 5 year distant di...

I seldom use them in this setting unless it's a micrometastasis or I am otherwise concerned about chemotherapy. These patients were the minority in MINDACT re Mammaprint, were not included at all in TailoRx re Oncotype Dx, and the node+ trials that tested Prosigna re ROR score were limited to postme...